Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Sales | 9,448 | 2,027 | 1,788 | 1,864 | 313 |
| Cost of Goods | 2,832 | 1,299 | 1,790 | N/A | N/A |
| Gross Profit | 6,616 | 728 | -2 | 261 | 313 |
| Operating Expenses | 21,192 | 23,232 | 29,042 | 34,665 | 30,395 |
| Operating Income | -13,744 | -22,205 | -28,254 | -32,801 | -30,082 |
| Interest Expense | 2,328 | 2,242 | 1,499 | 1,531 | 3,507 |
| Other Income | 72 | 238 | 569 | 792 | 753 |
| Pre-tax Income | -16,000 | -24,209 | -29,184 | -33,540 | -32,836 |
| Income Tax | N/A | -110 | N/A | N/A | N/A |
| Net Income Continuous | -16,000 | -24,099 | -29,184 | -33,082 | -32,836 |
| Net Income | $-16,000 | $-24,099 | $-29,184 | $-33,082 | $-32,836 |
| EPS Basic Total Ops | -0.35 | -0.63 | -0.89 | -1.24 | -1.22 |
| EPS Basic Continuous Ops | -0.35 | -0.63 | -0.89 | -1.24 | -1.22 |
| EPS Diluted Total Ops | -0.35 | -0.63 | -0.89 | -1.24 | -1.22 |
| EPS Diluted Continuous Ops | -0.35 | -0.63 | -0.89 | -1.24 | -1.22 |
| EBITDA(a) | $-13,016 | $-21,705 | $-27,754 | $-32,240 | $-29,489 |